A probabilistic approach for determining Monte Carlo beam source parameters: II. Impact of beam modeling uncertainties on dosimetric functions and treatment plans

Abstract

Abstract Objective. The Monte Carlo method is recognized as a valid approach for the evaluation of dosimetric functions for clinical use. This procedure requires the accurate modeling of the considered linear accelerator. In Part I, we propose a new method to extract the probability density function of the beam model physical parameters. The aim of this work is to evaluate the impact of beam modeling uncertainties on Monte Carlo evaluated dosimetric functions and treatment plans in the context of small fields. Approach. Simulations of output factors, output correction factors, dose profiles, percent-depth doses and treatment plans are performed using the CyberKnife M6 model developed in Part I. The optimized pair of electron beam energy and spot size, and eight additional pairs of beam parameters representing a 95% confidence region are used to propagate the uncertainties associated to the source parameters to the dosimetric functions. Main results. For output factors, the impact of beam modeling uncertainties increases with the reduction of the field size and confidence interval half widths reach 1.8% for the 5 mm collimator. The impact on output correction factors cancels in part, leading to a maximum confidence interval half width of 0.44%. The impact is less significant for percent-depth doses in comparison to dose profiles. For these types of measurement, in absolute terms and in comparison to the reference dose, confidence interval half widths less than or equal to 1.4% are observed. For simulated treatment plans, the impact is more significant for the treatment delivered with a smaller field size with confidence interval half widths reaching 2.5% and 1.4% for the 5 and 20 mm collimators, respectively. Significance. Results confirm that AAPM TG-157's tolerances cannot apply to the field sizes studied. This study provides an insight on the reachable dose calculation accuracy in a clinical setup.